Table 2 Percentage change from baseline in lipid variables at 16 weeks (ITT population). Doses were titrated from week 4 to week 16 in patients who had not reached the 1998 European LDL-C goal (< 3.0 mmol/L)
Variable | Least-squares mean percentage change from baseline to 16 weeks | Difference (95% CI) | p-value | |
|---|---|---|---|---|
Rosuvastatin 10–40 mg (n = 221) | Atorvastatin 10–80 mg (n = 220) | |||
LDL-C | -52.3 | -45.5 | -6.7 (-8.8, -4.7) | < 0.0001 |
TC | -35.4 | -31.3 | -4.1 (-5.8, -2.4) | < 0.0001 |
HDL-C | 5.3 | 4.0 | 1.3 (-1.3, 3.8) | NS |
TG | -21.2 | -21.1 | -0.1 (-5.6, 5.3) | NS |
Non-HDL-C | -45.0 | -39.6 | -5.5 (-7.4, -3.5) | < 0.0001 |
LDL-C/HDL-C ratio | -54.1 | -47.0 | -7.1 (-9.3, -4.9) | < 0.0001 |
Non-HDL-C/HDL-C ratio | -47.1 | -40.9 | -6.2 (-8.6, -3.9) | < 0.0001 |
TC/HDL-C ratio | -38.0 | -33.1 | -5.0 (-6.9, -3.0) | < 0.0001 |
Apo B | -45.2 | -40.1 | -5.1 (-7.2, -3.1) | < 0.0001 |
Apo A-I | 2.6 | -0.2 | 2.8 (1.0, 4.6) | 0.0024 |
Apo B/apo A-I ratio | -46.3 | -39.6 | -6.7 (-8.9, -4.6) | < 0.0001 |